All In MedTech

Device Trial Radar · NCT07210255

SAINT in Postpartum Depression (PPD)

A Randomized Controlled Multi-site Trial Evaluating SAINT for Postpartum Depression

Last checked: Nov 21, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Nov 1, 2025

Primary completion

Apr 30, 2029

Study completion Oct 31, 2029

Sponsor

Lead sponsor
Magnus MedicalNot on our public-company list
Sponsor type
Industry
Collaborators
Congressionally Directed Medical Research Programs
First posted
Oct 7, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a large, multi-site clinical trial testing whether Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a fast-acting form of repetitive transcranial magnetic stimulation (rTMS), can more effectively reduce symptoms of postpartum depression (PPD) compared to a sham treatment. It will enroll 192 women within 12 months postpartum who are experiencing depression, and will track their progress for up to 12 months. The trial's main goal is to see if SAINT leads to reduction in depression severity in women with postpartum depression.

Conditions

  • Postpartum Depression (PPD)

Interventions

  • SAINT Neuromodulation SystemDevice

    SAINT will be delivered via a MagPro X100 edition (MagVenture, Skovlunde, Denmark) TMS device equipped with a Cool-B65 A/P coil. The stimulation paradigm consists of 10 daily sessions (50 total sessions over 5 days) of SAINT stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be administered at 90% of the participant's resting motor threshold, with depth correction applied to adjust for the measured distance between the scalp and cortical surface. The stimulation target, the L-DLPFC, will be identified and localized by the study investigator using the Localite neuronavigation system.

  • Sham SAINT StimulationDevice

    Sham stimulation will be delivered using the MagVenture MagPro X100 TMS system with the Cool-B65 A/P coil and targeted to the L-DLPFC. The stimulation paradigm will be identical to the active SAINT stimulation with the exception that active stimulation will not be delivered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in depression symptom severity, assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), from baseline to 5 days post-treatment, which will be compared between the acute active SAINT and sham arms.Time frame: Baseline and 5 days post-acute treatment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UMass Chan Medical School

    Worcester, Massachusetts · Recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.